ESCulab

European screening centre; unique library for attractive biology
ESCULAB logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 12
Grant agreement number
806948

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
18 249 993
EFPIA in kind
17 669 327
Associated Partners
810 000
Total Cost
36 729 320

Summary

In the early stages of drug discovery, scientists screen large numbers of chemical compounds in the hunt for potential new drugs or other interesting molecules that could be used in drug development. Accessing large, high quality compound collections for this is a challenge; IMI’s European Lead Factory project, which ran from 2013 to 2018, set up a collection of over half a million compounds and a state-of-the-art high throughput screening centre that gave a massive boost to drug discovery programmes in universities, small biotechs and large companies across Europe. The aim of the ESCulab project is to build on the achievements of the European Lead Factory. This means that researchers with drug targets can apply to have their target screened free of charge against the project’s compound collection and get help developing any resulting hits further if they like. In total, ESCulab plans to run 185 new drug discovery projects during its lifetime. In the long term, the screening centre should become self-sustaining so that it can continue to provide these valuable services after the project has finished.

Participants Show participants on map

EFPIA companies
  • Astrazeneca AB, Södertälje, Sweden
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Grunenthal GMBH, Aachen, Germany
  • Institut De Recherches Servier, Suresnes, France
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany
  • Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany
  • UCB Biopharma SPRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • University Of Dundee, Dundee, United Kingdom
  • University of Oxford, Oxford, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Bioascent Discovery Limited, Newhouse, United Kingdom
  • Edelris SAS, Lyon, France
  • Mercatorial BV, Nijmegen, Netherlands
  • Pivot Park Screening Centre BV, Oss, Netherlands
  • Stichting Lygature, Utrecht, Netherlands
  • Taros Chemicals GMBH & Co Kg, Dortmund, Germany
Associated partners
  • Mmv Medicines For Malaria Venture Fondation, genevra, Switzerland
Non EFPIA companies
  • Mercaleads BV, Nijmegen, Netherlands
  • Sygnature Discovery Limited, Nottingham, United Kingdom
  • Syncom BV, Groningen, Netherlands

CONTACT

Project coordinator
Jon DE VLIEGER
STICHTING LYGATURE
jon.devlieger[at]lygature.org